Tolvaptan (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tolvaptan" in English language version.

refsWebsite

Global rank English rank

6fda.gov

447^th place

338^th place

5nih.gov

4^th place

3europa.eu

68^th place

117^th place

2medicines.org.uk

3,823^rd place

2,387^th place

1doi.org

2^nd place

1semanticscholar.org

11^th place

8^th place

1medicalnewstoday.com

3,011^th place

2,709^th place

1otsuka.co.jp

low place

1worldcat.org

5^th place

doi.org

Shoaf S, Elizari M, Wang Z, et al. (2005). "Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias". J Cardiovasc Pharmacol Ther. 10 (3): 165–71. doi:10.1177/107424840501000304. PMID 16211205. S2CID 39158242.

europa.eu

ema.europa.eu

"Samsca EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 14 December 2020.
"Jinarc EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 14 December 2020.
"Tolvaptan Accord: Pending EC decision". European Medicines Agency (EMA). 26 January 2023. Retrieved 28 January 2023.

fda.gov

accessdata.fda.gov

"Drug Approval Package: Samsca (Tolvaptan) Tablets NDA #022275". U.S. Food and Drug Administration (FDA). 21 July 2009. Retrieved 15 August 2020.
"Drug Approval Package: Jynarque (tolvaptan)". U.S. Food and Drug Administration (FDA). 8 June 2018. Retrieved 15 August 2020.
"Tolvaptan Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 6 April 2012. Retrieved 15 August 2020.
"Drugs@FDA: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 15 August 2020.

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

fda.gov

"U.S. Food and Drug Administration." Samsca (Tolvaptan): Drug Safety Communication. N.p., 30 Apr. 2013. Web. 1 June 2014. <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm350185.htm>^{[dead link]}

medicalnewstoday.com

"Otsuka Maryland Research Institute, Inc. Granted Fast Track Designation For Tolvaptan In PKD". Medical News Today. Healthline Media UK Ltd. Retrieved 6 December 2018.

medicines.org.uk

"Samsca 15 mg tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 14 December 2020.
"Jinarc 15 mg tablets - Summary of Product Characteristics (SmPC)". (emc). 21 April 2020. Retrieved 14 December 2020.

nih.gov

dailymed.nlm.nih.gov

"Jynarque- tolvaptan kit Jynarque- tolvaptan tablet". DailyMed. 31 March 2020. Retrieved 14 December 2020.
"Samsca- tolvaptan tablet". DailyMed. 26 October 2020. Retrieved 14 December 2020.
"Samsca- tolvaptan tablet". DailyMed. 28 May 2019. Retrieved 15 August 2020.
"Jynarque- tolvaptan kit Jynarque- tolvaptan tablet". DailyMed. 31 March 2020. Retrieved 15 August 2020.

pubmed.ncbi.nlm.nih.gov

Shoaf S, Elizari M, Wang Z, et al. (2005). "Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias". J Cardiovasc Pharmacol Ther. 10 (3): 165–71. doi:10.1177/107424840501000304. PMID 16211205. S2CID 39158242.

otsuka.co.jp

"Otsuka Obtains Approval in Japan for SAMTASU® for I.V. Infusion, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema" (Press release). March 28, 2022. Retrieved June 11, 2022.

semanticscholar.org

api.semanticscholar.org

Shoaf S, Elizari M, Wang Z, et al. (2005). "Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias". J Cardiovasc Pharmacol Ther. 10 (3): 165–71. doi:10.1177/107424840501000304. PMID 16211205. S2CID 39158242.

worldcat.org

search.worldcat.org

Goodman & Gilman's the pharmacological basis of therapeutics. Brunton, Laurence L, Knollmann, Björn C, Hilal-Dandan, Randa (Thirteenth ed.). New York. 5 December 2017. ISBN 9781259584732. OCLC 994570810.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)